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Abstract: With insights gained through molecular profiling, cancer is recognized as a heterogeneous disease with distinct subtypes and 
outcomes that can be predicted by a limited number of biomarkers. Statistical methods such as supervised classification and machine 
learning identify distinguishing features associated with disease subtype but are not necessarily clear or interpretable on a biological 
level. Genes with bimodal transcript expression, however, may serve as excellent candidates for disease biomarkers with each mode of 
expression readily interpretable as a biological state. The recent article by Wang et al, entitled “The Bimodality Index: A Criterion for 
Discovering and Ranking Bimodal Signatures from Cancer Gene Expression Profiling Data,” provides a bimodality index for identify-
ing and scoring transcript expression profiles as biomarker candidates with the benefit of having a direct relation to power and sample 
size. This represents an important step in candidate biomarker discovery that may help streamline the pipeline through validation and 
clinical application.
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High-throughput gene expression assays are capable 
of generating large-scale datasets that are useful in 
gaining insight to healthy biological systems, disease 
phenotypes, and biomarkers that are representative 
of these phenotypes. The recent publication by Wang 
et al1 provides a sound approach for mining through 
these expression datasets to identify and rank a class 
of genes, with bimodal expression profiles, that may 
serve as ideal biomarker candidates. Biomarkers that 
correspond with disease phenotypes are a useful tool 
for the diagnosis, treatment, and prognosis of disease. 
Cancer, as a heterogeneous disease, has many sub-
types that respond differently to treatment and have 
different overall prognosis.2 Biomarkers with accu-
rate and reliable assays can be useful in identifying 
specific cancer subtypes and guiding treatment in the 
age of personalized or precision medicine.
Molecular  profiles  with  bimodal  expression 
provide excellent candidates for biomarkers because 
the modes can be used to classify samples into two 
distinct  expression  states.  During  the  biomarker 
discovery process, a bimodal expression profile may 
be considered meaningful when the modes of expres-
sion correspond with binary biological phenotypes, 
such as healthy and disease states. A biomarker that 
is deemed meaningful then needs follow up studies 
to  determine  the  sensitivity  and  specificity  before 
it  could  be  considered  accurate  and  reliable  for 
practical  application.  However,  it  is  typically  rare 
that a molecule associated with a disease phenotype 
can be assayed with the sensitivity and specificity 
required for a clinical diagnostic test.3 One advantage 
of biomarker candidates with bimodal profiles at the 
transcript level is that they may be easily translated to 
the protein level and IHC staining, for a greater vari-
ety of available assays. Bimodal transcript expression 
typically corresponds with membrane and extracellu-
lar proteins, where molecules used as cancer biomark-
ers primarily localize.3,4 A variety of available assays 
may need to be evaluated at the gene or protein level 
before an adequate reliability is obtained. Estrogen 
receptor,  for  example,  has  served  as  an  important 
biomarker in breast cancer, but assays have had vary-
ing success and some but not all assays capture a 
bimodal distribution.5,6
The method presented in Wang et al was applied 
to  the  MDA133  breast  cancer  microarray  dataset 
previously published by Hess et al.1,7 The MDA133 
microarray  dataset  is  accompanied  by  clinical 
information including immunohistochemistry (IHC) 
scores for markers currently used to evaluate breast 
cancer, including estrogen receptor (ESR1), proges-
terone receptor (PGR), and human epidermal growth 
factor receptor 2 (HER2, or ERBB2). These mark-
ers define subcategories of breast cancer that differ in 
response to therapy as well as overall survival.2 IHC 
scores for these proteins are graded by pathologists 
and used to guide the diagnosis and treatment of breast 
cancer subtypes, and there is evidence that transcript 
profiles for these markers correlate well with protein 
measures.8,9 The IHC profiles of these markers, based 
on  the  dataset  from  Hess  et  al  available  at  http://
bioinformatics.mdanderson.org/pubdata.html, follow 
a bimodal distribution (Fig. 1).7 The bimodal distribu-
tion is suitable for defining a cut point between the two 
modal peaks. The cut-point used for the IHC scores 
corresponding to each molecule in the Hess et al7 
dataset demonstrate this, and are identified with the 
dashed vertical red line in Figure 1. With the estab-
lished bimodal distributions of IHC scores for these 
markers, Wang et al1 investigated the gene expression 
profiles and Bimodality Index for these three genes, 
and found that they all had high scores for bimodal-
ity. The bimodal expression profiles for these three 
transcripts,  using  log2  transformed  data  from  Hess 
et al7 are shown in Figure 2. The software package for 
computing the bimodality index also provides param-
eters  for  the  bimodal  mixture  distributions,  which 
were  used  to  define  marker  classification  thresh-
olds shown as dashed vertical red lines in Figure 2. 
While the authors only commented on the proportion 
of samples represented by each mode, the mode of 
expression from the transcript profile is shown by the 
degree of shading to correlate well with the mode of 
expression from the IHC score. This serves not only 
as a validation for the bimodality index in real data, 
but also demonstrates that an automated transcript-
based assay may be an attractive alternative to manu-
ally scored IHC.
The  correspondence  between  the  protein  and 
transcript  level  expression  for  these  three  markers 
shows much promise for the application of the bimo-
dality  index  to  biomarker  discovery.  However,  a 
bimodal expression profile alone does not imply that 
a molecule will have a meaningful correlation with a 
biological or clinical variable of interest. The authors Bimodal gene expression and biomarker discovery
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Figure 1. Histograms representing IHc scores for esR1, pGR, and 
eRBB2. These three IhC markers appear as bimodal distributions in 
the MD Anderson 133 sample dataset. Dashed vertical red lines define 
thresholds  for  dichotomizing  values  as  marker-positive  and  marker- 
negative.
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Figure 2. Histograms representing transcript level distributions for 
the esR1, pGR, and eRBB2 genes. The transcripts for these three genes 
have bimodal distributions with the dashed vertical line representing the 
classification  threshold  between  the  two  modes.  The  histogram  shad-
ing represents the proportion of marker-positive IhC scores in each bin 
(Dark blue corresponds to marker-negative IhC and white corresponds to 
marker-positive IhC). The solid red line represents the bimodal distribution 
density estimate based on parameters from the bimodality index software 
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provide  an  example  of  a  problematic  candidate, 
where the marker creatine kinase, brain (CKB) has 
a strong bimodal profile that appears to be associated 
with breast cancer, and furthermore, advanced stage 
of disease, but provided limited value as a prognostic 
marker in this disease.10 Recognizing that many bio-
marker candidates will turn out to be false positives 
emphasizes the advantage to using a score such as the 
bimodality index, in that it relates directly to power 
and sample sizes and provides a ranking system for 
the  systematic  assessment  and  validation  of  bio-
marker candidates. This aspect should prove valuable 
in efficiently evaluating biomarker candidates from 
discovery  through  validation  to  establish  clinically 
relevant molecules and assays.
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